Disgorgement Offers "Innovative Approach" To GMP Compliance - FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA will look to recover profits from companies as a penalty for regulatory violations even in cases not involving the future sales of products deemed medically necessary.